Contacts Investors Media Traci McCarty Debra Charlesworth BioMarin Pharmaceutical IncBioMarin Pharmaceutical Inc 415 4557558 415 4557451 SOURCE BioMarin Pharmaceutical Inc102023 651 PM BioMarin Receives Complete Response Letter CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A  Au httpsinvestorsbiomarincom20200819BioMarinReceivesCompleteResponseLetterCRLfromFDAforValoctocogeneRoxaparvovecGeneTherapyforSe 66Navigate Our Motivation Our Treatments Our Company Investors  MediaAbout Our History Our Products Our Pipeline Leadership Team Board of Directors Diversity Equity  Inclusion Contact Global Contact Information Our Locations Report a Product Complaint Report Adverse Event Publication Data Request Funding  SupportConnect Careers LinkedIn Facebook Instagram YouTube Privacy Policy Terms of Use Site Map Supplier Information Slavery Act Statement Glossary Contact Us  2023 BioMarin